Helsel Dave

SEC source: 0001140361-23-036119 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,289

F2 · shares: The exempt disposition of 365 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036119 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,654

F1 · shares: The exempt disposition of 332 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-23-035731 · form4.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,329

Underlying: Common Stock · 22,329 shares

Expires 2033-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-035731 · form4.xml · derivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,578

Underlying: Common Stock · 21,578 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-23-035731 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,986

F1 · shares: The acquisition of 10,789 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,789 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-036321 · form4.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-036321 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,085

F2 · shares: The exempt disposition of 1,575 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036321 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 4,371 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044839 · form4.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044839 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,462

F2 · shares: The exempt disposition of 3,477 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044839 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 9,650 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035083 · form4.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,197

F2 · shares: The exempt disposition of 313 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035083 · form4.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,510

F1 · shares: The exempt disposition of 679 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-23-001649 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,189

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.94 to $12.97, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-014709 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,822

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.43 to $22.46, inclusive. The reporting person has provided to AngioDynamics, Inc. (the "Company"), and undertakes to provide to any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-014373 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,646

Underlying: Common Stock · 8,646 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014373 · doc1.xml · derivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,381

Underlying: Common Stock · 7,381 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014373 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,822

F1 · shares: The acquisition of 3,691 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,691 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-013850 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,945 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,480 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,480 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,480 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001567619-22-013850 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,131

F2 · shares: The exempt disposition of 1,223 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-013850 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,480 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-009209 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,874

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.43 to $22.44, inclusive. The reporting person has provided to AngioDynamics, Inc. (the "Company"), and undertakes to provide to any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-018544 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,387

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.95 to $28.05, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-015952 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,945 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 6,945 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015952 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,719

F2 · shares: The exempt disposition of 788 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015952 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 2,685 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-016019 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,834 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 9,834 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 11,406 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016019 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,881

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 3,347 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016019 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 11,406 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013925 · doc1.xml · derivative · entry 6

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

Underlying: Common Stock · 11,026 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013925 · doc1.xml · derivative · entry 5

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,116

Underlying: Common Stock · 8,116 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 4

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,822

F4 · shares: The acquisition of 4,058 shares of Common Stock of the Company represents 4,058 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022716 · doc1.xml · derivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

Underlying: Common Stock · 11,026 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of stock options of AngioDynamics, Inc., which contained an administrative error as to the exercise price of such options.

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,764

F3 · shares: The exempt disposition of 417 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,181

F2 · shares: The exempt disposition of 294 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,475

F1 · shares: The exempt disposition of 640 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-008147 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,115

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.90 to $24.05, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-20-021448 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,615

F1 · shares: The exempt disposition of 733 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on December 18, 2017.

SEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,348

F3 · shares: The exempt disposition of 153 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,501

F2 · shares: The exempt disposition of 207 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,708

F1 · shares: The exempt disposition of 254 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-20-013439 · doc1.xml · derivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,196

Underlying: Common Stock · 22,196 shares

Expires 2030-07-14

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-013439 · doc1.xml · derivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,081

Underlying: Common Stock · 15,081 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-20-013439 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,962

F1 · shares: This acquisition of 7,540 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,540 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-19-023485 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,422

F1 · shares: The exempt disposition of 736 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on December 18, 2017.

SEC source: 0001567619-19-019771 · doc1.xml · derivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,945

Underlying: Common Stock · 6,945 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-015201 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,158

F2 · shares: The exempt disposition of 172 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015201 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,330

F1 · shares: The exempt disposition of 233 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015047 · doc1.xml · derivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,615

Underlying: Common Stock · 11,615 shares

Expires 2029-07-17

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-015047 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,563

F1 · shares: This acquisition of 3,473 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,473 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023.